^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

bizalimogene ralaplasmid (VGX-3100)

i
Other names: VGX-3100, VGX 3100, pGX-3002, ABC-3100
Associations
Company:
ApolloBio, Inovio
Drug class:
HPV-16 E6 protein inhibitor, HPV-16 E7 protein inhibitor
Associations
1m
VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions (clinicaltrials.gov)
P2, N=35, Active, not recruiting, AIDS Malignancy Consortium | Recruiting --> Active, not recruiting | N=80 --> 35 | Trial completion date: Sep 2029 --> Jan 2027 | Trial primary completion date: Sep 2029 --> Jan 2026
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
|
PD-L1 expression
|
bizalimogene ralaplasmid (VGX-3100)